Abstract: The present invention relates to an oral pharmaceutical composition for increasing hypoxia tolerance, characterized in that the pharmaceutical composition comprises active ingredient L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, active ingredient trimetazidine or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary material, and 100:1 is the weight ratio of L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof and trimetazidine or pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof, and also can contain trimetazidine or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an oral pharmaceutical composition for increasing hypoxia tolerance, characterized in that the pharmaceutical composition comprises active ingredient L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, active ingredient trimetazidine or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary material, and 100:1 is the weight ratio of L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof and trimetazidine or pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof, and also can contain trimetazidine or a pharmaceutically acceptable salt thereof.

Abstract: Arsenic compounds of general formula (I), their preparation methods, the pharmaceutical compositions containing the compounds, and their uses in the manufacture of medicaments for treating cancer, particularly leukemia, are disclosed.

Abstract: The present invention relate to a preparation method of high-purity L-carnitine which belongs to an important technique of quality control in different steps of chiral medicine production.

Abstract: A preparation method and its use of derivatization reagent for detecting L-carnitine or D-carnitine are provided. The present reagent is stable. It can be used for detecting L-carnitine or D-carnitine accurately and sensitively. That is to say, the reagent is applied to detecting the amount of synthesized or natural L-carnitine and the amount of mixing D-carnitine. The compound reagent is used for determining the chiral isomers of chemicals, biological reagents, health care reagents, cosmetic, body fluids and various foods, which contain L-carnitine or/and D-carnitine, and optical isomers of other chiral amino acids.

Abstract: This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its medicative salts in the composition is effective amount for treating myocardial ischemia and reducing the area of myocardial infarction.

Abstract: Arsenic compounds of general formula (I), their preparation methods, the pharmaceutical compositions containing the compounds, and their uses in the manufacture of medicaments for treating cancer, particularly leukemia, are disclosed.

Abstract: A preparation method and its use of derivatisation reagent for detecting L-carnitine or D-carnitine are provided. The present reagent is stable. It can be used for detecting L-carnitine or D-carnitine accurately and sensitively. That is to say, the reagent is applied to detecting the amount of synthesized or natural L-carnitine and the amount of mixing D-carnitine. The compound reagent is used for determining the chiral isomers of chemicals, biological reagents, health care reagents, cosmetic, body fluids and various foods, which contain L-carnitine or/and D-carnitine, and optical isomers of other chiral amino acids.

Abstract: The present invention relate to a preparation method of high-purity L-carnitine which belongs to an important technique of quality control in different steps of chiral medicine production.

Abstract: A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided.

Abstract: This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its medicative salts in the composition is effective amount for treating myocardial ischemia and reducing the area of myocardial infarction.

Abstract: A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided.

Abstract: This invention relates to the composition of medicine, also a health-care product, cosmetics for treating chloasma and the method of the composition preparation and application. The composition contains active extracts of atractylodes lancea, semen coicis, and phellodendron amurense rupr, which are ruptured by solvent in weight ratio of 1:0.5-5:0.5-5.